Ligand Pharmaceuticals (LGND) Return on Capital Employed (2011 - 2026)
Ligand Pharmaceuticals (LGND) reported Return on Capital Employed of 6.28% for Q1 2026, up 1343.0% on a YoY basis from 0.44% in Q1 2025, and up 126.94% sequentially from 2.77% in Q4 2025.
Ligand Pharmaceuticals (LGND) Return on Capital Employed (2011 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 16 years of Return on Capital Employed data on file, last reported at 6.28% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1343.0% year-over-year to 6.28%; the trailing twelve-month figure through Mar 2026 stood at 6.28% (up 1343.0% YoY), and the FY2025 full-year result was 3.38%, up 611.0% from the prior year.
- Return on Capital Employed advanced to 6.28% in Q1 2026, from 2.77% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.74% in Q1 2022 to a low of 7.15% in Q1 2025.
- A 5-year average of 1.15% and a median of 0.59% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 797 bps in 2022 and surged 1343 bps in 2026, its largest moves.
- Tracing LGND's Return on Capital Employed over 5 years: stood at 0.38% in 2022, then jumped by 317 bps to 1.57% in 2023, then sank by 258 bps to 2.48% in 2024, then surged by 212 bps to 2.77% in 2025, then soared by 127 bps to 6.28% in 2026.
- Business Quant data shows LGND's Return on Capital Employed at 6.28% in Q1 2026, 2.77% in Q4 2025, and 1.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 6.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.28% |
| Dec 31, 2025 | 2.77% |
| Sep 30, 2025 | 1.48% |
| Jun 30, 2025 | -3.97% |
| Mar 31, 2025 | -7.15% |
| Dec 31, 2024 | -2.48% |
| Sep 30, 2024 | -1.84% |
| Jun 30, 2024 | -1.88% |
| Mar 31, 2024 | 0.09% |
| Dec 31, 2023 | 1.57% |
| Sep 30, 2023 | -0.64% |
| Jun 30, 2023 | 0.59% |
| Mar 31, 2023 | 2.20% |
| Dec 31, 2022 | 0.38% |
| Sep 30, 2022 | 6.55% |
| Jun 30, 2022 | 6.96% |
| Mar 31, 2022 | 8.74% |
| Dec 31, 2021 | 8.35% |
| Sep 30, 2021 | 7.25% |
| Jun 30, 2021 | 6.30% |